3-chloro-6-ethoxy-1,2,4-benzotriazine 1-oxide | 863973-47-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 3-chloro-6-ethoxy-1,2,4-benzotriazine 1-oxide
• 英文别名: 3-Chloro-6-ethoxy-1-oxido-1,2,4-benzotriazin-1-ium
• CAS: 863973-47-1
• 化学式: C₉H₈ClN₃O₂
• 分子量: 225.634
• InChiKey: JXUBDMFQQAJDBT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  60.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-氨丙基)吗啉 、 3-chloro-6-ethoxy-1,2,4-benzotriazine 1-oxide 以 乙二醇二甲醚 为溶剂， 反应 8.0h， 以97%的产率得到6-ethoxy-N-[3-(4-morpholinyl)propyl]-1,2,4-benzotriazin-3-amine 1-oxide
  参考文献：
  名称：

  Pharmacokinetic/Pharmacodynamic Model-Guided Identification of Hypoxia-Selective 1,2,4-Benzotriazine 1,4-Dioxides with Antitumor Activity: The Role of Extravascular Transport

  摘要：

  Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotriazine 1,4-dioxide (BTO) analogues of TPZ to improve activity against hypoxic cells by increasing extravascular transport. The 6 substituents modified lipophilicity and rates of hypoxic metabolism. 3-Alkylamino substituents increased aqueous solubility and also influenced lipophilicity and hypoxic metabolism. PK/PD model-guided screening was used to select six BTOs for evaluation against hypoxic cells in HT29 human tumor xenografts. All six BTOs were active in vivo, and two provided greater hypoxic cell killing than TPZ because of improved transport and/or plasma PK. This PK/PD model considers two causes of therapeutic failure (limited tumor penetration and poor plasma pharmacokinetics) often not addressed early in drug development and provides a general strategy for selecting candidates for in vivo evaluation during lead optimization.

  DOI：

  10.1021/jm070670g
• 作为产物：
  描述：

  6-ethoxy-1,2,4-benzotriazin-3-amine 1-oxide 在 三氟乙酸 、 sodium nitrite 、 三氯氧磷 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 4.0h， 以71%的产率得到3-chloro-6-ethoxy-1,2,4-benzotriazine 1-oxide
  参考文献：
  名称：

  [EN] NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES
  [FR] 1,2,4-BENZOTRIAZINE-1,4-DIOXYDES

  摘要：

  本发明提供了一种简化的特征集，可用于选择对人类肿瘤异种移植物中的缺氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物（TPZ类似物），并进一步提供了一种新型的1,2,4-苯并三氮唑-1,4-二氧化物（TPZ类似物），预测其对肿瘤的体内活性，以及它们的制备和用作缺氧选择性细胞毒药物和放射增敏剂用于癌症治疗，单独或与放射线和/或其他抗癌药物结合使用。

  公开号：

  WO2005082867A1

文献信息

• Novel 1,2,4-benzotriazine-1,4-dioxides
  申请人：Denny Alexander William

  公开号：US20070197534A1

  公开（公告）日：2007-08-23

  The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a novel class of 1,2,4-benzotriazine-1,4-dioxides (TPZ analogues) with predicted in vivo activity against tumours, to their preparation, and to their use as hypoxia-selective cytotoxic drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明提供了一组简化的特征，可用于选择对人类肿瘤异种移植物中的低氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物化合物（TPZ类似物），并进一步提供一种新型的1,2,4-苯并三氮唑-1,4-二氧化物（TPZ类似物），预测其对肿瘤的体内活性，以及它们的制备和作为低氧选择性细胞毒性药物和放射增敏剂用于癌症治疗，单独或与放射线和/或其他抗癌药物联合使用。
• NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES
  申请人：AUCKLAND UNISERVICES LIMITED

  公开号：EP1723125A1

  公开（公告）日：2006-11-22
• US7816521B2
  申请人：——

  公开号：US7816521B2

  公开（公告）日：2010-10-19
• [EN] NOVEL 1,2,4-BENZOTRIAZINE-1,4-DIOXIDES<br/>[FR] 1,2,4-BENZOTRIAZINE-1,4-DIOXYDES
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2005082867A1

  公开（公告）日：2005-09-09

  The present invention provides a simplified set of characteristics that can be used to select 1,2,4 benzotriazine 1,4 dioxide compounds (TPZ analogues) with therapeutic activity against hypoxic cells in human tumour xenografts, and to further provide a novel class of 1,2,4-benzotriazine-1,4-dioxides (TPZ analogues) with predicted in vivo activity against tumours, to their preparation, and to their use as hypoxia-selective cytotoxic drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明提供了一种简化的特征集，可用于选择对人类肿瘤异种移植物中的缺氧细胞具有治疗活性的1,2,4-苯并三氮唑-1,4-二氧化物（TPZ类似物），并进一步提供了一种新型的1,2,4-苯并三氮唑-1,4-二氧化物（TPZ类似物），预测其对肿瘤的体内活性，以及它们的制备和用作缺氧选择性细胞毒药物和放射增敏剂用于癌症治疗，单独或与放射线和/或其他抗癌药物结合使用。
• Pharmacokinetic/Pharmacodynamic Model-Guided Identification of Hypoxia-Selective 1,2,4-Benzotriazine 1,4-Dioxides with Antitumor Activity: The Role of Extravascular Transport
  作者：Michael P. Hay、Kevin O. Hicks、Frederik B. Pruijn、Karin Pchalek、Bronwyn G. Siim、William R. Wilson、William A. Denny

  DOI：10.1021/jm070670g

  日期：2007.12.13

  Pharmacokinetic/pharmacodynamic (PK/PD) modeling has shown the antitumor activity of tirapazamine (TPZ), a bioreductive hypoxia-selective cytotoxin, to be limited by poor penetration through hypoxic tumor tissue. We have prepared a series of 1,2,4-benzotriazine 1,4-dioxide (BTO) analogues of TPZ to improve activity against hypoxic cells by increasing extravascular transport. The 6 substituents modified lipophilicity and rates of hypoxic metabolism. 3-Alkylamino substituents increased aqueous solubility and also influenced lipophilicity and hypoxic metabolism. PK/PD model-guided screening was used to select six BTOs for evaluation against hypoxic cells in HT29 human tumor xenografts. All six BTOs were active in vivo, and two provided greater hypoxic cell killing than TPZ because of improved transport and/or plasma PK. This PK/PD model considers two causes of therapeutic failure (limited tumor penetration and poor plasma pharmacokinetics) often not addressed early in drug development and provides a general strategy for selecting candidates for in vivo evaluation during lead optimization.